Cardiac rhythm monitoring has expanded dramatically in capability and modality over the past decade — from 24-hour Holter monitors to 30-day patch monitors to implantable loop recorders with 3-year monitoring capacity, and most recently wrist-worn ECG smartwatches with FDA clearance for AFib detection. Matching the right monitoring modality to the clinical question — arrhythmia characterization, syncope workup, cryptogenic stroke evaluation, drug efficacy monitoring — is essential for both diagnostic yield and cost-effective utilization. Our diagnostic equipment section includes cardiac monitoring accessories, ECG electrodes, and telemetry supplies for inpatient and outpatient programs.
The Monitoring Modality Selection Guide
12-lead ECG: gold-standard for acute arrhythmia characterization, acute coronary syndrome, conduction abnormalities, and electrolyte effects; limited by the moment of capture — appropriate for patients with acute or ongoing symptoms. 24–48 hour Holter monitor: appropriate for symptomatic arrhythmias occurring daily or every other day; limitation is low diagnostic yield for less-frequent events. 7–30 day ambulatory monitor (Zio XT patch, Biotel BeatLogic): waterproof adhesive single-lead ECG patch worn continuously — dramatically higher arrhythmia detection compared to Holter for less-frequent symptoms (diagnostic yield 30–60% for Zio XT vs 5–20% for Holter in symptomatic patients). AHA/HRS guidelines recommend 30-day monitoring as the first-line approach for suspected arrhythmia symptoms occurring less than daily. Extended mobile cardiac outpatient telemetry (MCOT): real-time monitored 30-day event recording with automatic arrhythmia detection — highest sensitivity for life-threatening arrhythmia requiring immediate notification; indicated for high-risk patients (pre-syncope with structural heart disease, syncope with QTc abnormality). ECG electrodes, lead wires, and Holter accessories are available in our diagnostic equipment catalog.
Implantable Loop Recorder (ILR) for Cryptogenic Stroke
The CRYSTAL-AF trial established ILR superiority over standard monitoring for AFib detection in cryptogenic stroke — revealing paroxysmal AFib in 30% of patients at 3 years vs 3% with standard monitoring. Current ESC guidelines recommend ILR implantation in cryptogenic stroke patients (those with no identified cause after standard workup) to guide anticoagulation decision-making. Medtronic Reveal LINQ and Abbott Confirm Rx are FDA-cleared ILRs inserted under local anesthesia as an outpatient procedure, wirelessly transmitting to patient bedside monitors and clinic servers. The clinical supply chain for ILR programs includes local anesthetic supplies, sterile procedure trays, and wound care products from our wound care and OR supply sections.
